Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADICAL Trial: Neoadjuvant Short- vs Long-Course Radiotherapy With Dual Immunotherapy in Locally Advanced Rectal Cancer
ChiCTR2600127278Phase 3Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of paromlimab, tuvonralimab, tislelizumab and Capecitabine + oxaliplatin in rectal adenocarcinoma (3 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Pathologic complete response. Started Jun 2026; status: recruiting.
02
Drugs
paromlimabtuvonralimabtislelizumabCapecitabine + oxaliplatin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600127278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127278.